Myomo arrives at its third-quarter report with an unusual setup: management has told investors to expect more than Wall Street is willing to pencil in. After a second quarter that broke a string of cautious calls with 21% revenue growth, a guidance raise and a near-breakeven adjusted EBITDA result, the question is whether that reacceleration was a durable turn or a strong quarter flattered by timing. The answer should come after the close on November 9.

Consensus calls for revenue of $11.3 million, up 12% from $10.1 million a year ago, and a loss of $0.08 per share, an improvement from the $0.09 loss in the year-ago period. That revenue estimate sits below management's third-quarter guidance of $11.5 million to $12.0 million and would actually represent a sequential decline from the $11.7 million reported last quarter. Analysts have moved up toward the company's range since it was issued, but they remain skeptical. The full-year math adds another layer. With roughly $21.8 million booked in the first half, the raised 2026 outlook of $45 million to $47 million implies a second half of about $23 million to $25 million, so a third quarter near the low end or below would put pressure on the fourth quarter to carry the year.

The operating story management told last quarter rests on a few measurable claims. The first is the shift toward recurring patient sources, which reached 53% of revenue, hitting the 50% goal six months early, alongside referral sites that doubled to more than 300 and U.S. orthotics and prosthetics revenue that roughly doubled year over year. Continued gains in that mix, plus orders holding near the record 255 booked in the second quarter, would validate the idea that Myomo is building a steadier, less advertising-dependent funnel. The second is the pipeline. The headline figure fell to 1,491 as the company purged stalled Medicare Advantage patients, and management steered attention to pipeline additions instead. If additions slip this quarter, that reframing gets harder to accept, especially since the company already flagged a website glitch in the second quarter and midterm election advertising competition as headwinds for the back half.

Margins and cash are the other pillars. Gross margin jumped to 72.1% on pricing, cheaper mobile-app components and lower overhead, even as average selling price eased to about $55,500, in line with the normalization management had telegraphed. Holding margins near that level while ASP settles would show the step-up was structural. Investors should also check progress against the promise of total second-half cash burn below $2 million, and remember that part of the EBITDA improvement came from leaning on stock-based compensation. Non-cash charges tied to the Avenue Capital loan can also distort reported earnings, so the per-share figure may matter less than cash use. Updates on the University of Utah randomized trial, now half enrolled with a six-month readout targeted for the second half, the Optum workers' compensation contract, new Elevance states and the hand-only device for Germany could add color but are unlikely to move this quarter's numbers.

The market has rewarded the turnaround, with shares up about 18% since the last report while the S&P 500 slipped, yet the enthusiasm has cooled. At $1.20, the stock sits well below its post-earnings high of $1.89 and closer to the $1.02 low, though still above its 200-day average near $1.08. Sentiment has also soured, moving to 38.4% bearish from 21.3% heading into the prior report, suggesting traders doubt the momentum will hold.

That skepticism frames the central issue. Myomo needs to land inside its own guidance range, keep recurring-source growth and orders moving up, and reaffirm the full-year outlook without leaning heavily on the fourth quarter. Do that, and the second quarter starts to look like a genuine inflection. Fall back toward the Street's more cautious number, and the rebound will look more like a one-quarter bounce.